{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:52:11Z","timestamp":1783403531768,"version":"3.54.6"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.autrev.2020.102534","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T02:56:50Z","timestamp":1585364210000},"page":"102534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of complement activation in autoimmune liver disease"],"prefix":"10.1016","volume":"19","author":[{"given":"Maaike","family":"Biewenga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arantza","family":"Farina Sarasqueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten E.","family":"Tushuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline S.M.","family":"de Jonge-Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"van Hoek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leendert A.","family":"Trouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.autrev.2020.102534_bb0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.imlet.2011.02.014","article-title":"Role of complement in innate immunity and host defense","volume":"138","author":"Trouw","year":"2011","journal-title":"Immunol Lett"},{"issue":"9","key":"10.1016\/j.autrev.2020.102534_bb0010","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1136\/annrheumdis-2014-205287","article-title":"The complement system in systemic lupus erythematosus: an update","volume":"73","author":"Leffler","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102534_bb0015","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3389\/fimmu.2018.01057","article-title":"Complement in the initiation and evolution of rheumatoid arthritis","volume":"9","author":"Holers","year":"2018","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0020","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.autrev.2020.102534_bb0025","first-page":"102424","article-title":"Complement alternative pathway in ANCA-associated vasculitis: two decades from bench to bedside","author":"Brilland","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.autrev.2020.102534_bb0030","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.autrev.2020.102534_bb0035","first-page":"1379","article-title":"Eculizumab in atypical hemolytic-uremic syndrome","volume":"369","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102534_bb0040","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fimmu.2019.00672","article-title":"Complement therapeutics in autoimmune disease","volume":"10","author":"Thurman","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102534_bb0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molimm.2015.05.010","article-title":"C1q, antibodies and anti-C1q autoantibodies","volume":"68","author":"Beurskens","year":"2015","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102534_bb0050","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/hep.30508","article-title":"The role of complement in liver injury, regeneration and transplantation","volume":"70","author":"Thorgersen","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.autrev.2020.102534_bb0055","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102534_bb0060","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cei.12952","article-title":"Production of complement components by cells of the immune system","volume":"188","author":"Lubbers","year":"2017","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1136\/gut.40.4.544","article-title":"Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality","volume":"40","author":"Homann","year":"1997","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0070","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2020.102534_bb0075","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.clinre.2016.06.003","article-title":"Liver immunology: how to reconcile tolerance with autoimmunity","volume":"41","author":"Grant","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0080","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jhep.2009.03.006","article-title":"Operational tolerance after liver transplantation","volume":"50","author":"Orlando","year":"2009","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102534_bb0085","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1034\/j.1600-6143.2003.00050.x","article-title":"Incidence of renal and liver rejection and patient survival rate following combined liver and kidney transplantation","volume":"3","author":"Creput","year":"2003","journal-title":"Am J Transplant"},{"issue":"19","key":"10.1016\/j.autrev.2020.102534_bb0090","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.3748\/wjg.v22.i19.4651","article-title":"Auto immune hepatitis","volume":"22","author":"van Gerven","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41424-018-0028-1","article-title":"Role of age in presentation, response to therapy and outcome of autoimmune hepatitis","volume":"9","author":"Baven-Pronk","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102534_bb0100","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"van Gerven","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102534_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaut.2013.08.001","article-title":"Clinical significance of autoantibodies in autoimmune hepatitis","volume":"46","author":"Liberal","year":"2013","journal-title":"J Autoimmun"},{"issue":"3","key":"10.1016\/j.autrev.2020.102534_bb0110","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0115","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","author":"European Association for the Study of the, L","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102534_bb0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.autrev.2020.102534_bb0125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1479-5876-11-146","article-title":"Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients","volume":"11","author":"Li","year":"2013","journal-title":"J Transl Med"},{"issue":"7","key":"10.1016\/j.autrev.2020.102534_bb0130","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.humpath.2007.12.014","article-title":"An immunohistochemical evaluation of C4d deposition in pediatric inflammatory liver diseases","volume":"39","author":"Bouron-Dal Soglio","year":"2008","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.autrev.2020.102534_bb0135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/MPG.0b013e3182a98dbe","article-title":"Humoral immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic anemia","volume":"58","author":"Whitington","year":"2014","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0140","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/liv.12434","article-title":"Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study","volume":"34","author":"Boonstra","year":"2014","journal-title":"Liver Int"},{"issue":"9777","key":"10.1016\/j.autrev.2020.102534_bb0145","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"issue":"1.2","key":"10.1016\/j.autrev.2020.102534_bb0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.64.7","article-title":"Primary biliary cholangitis: its pathological characteristics and immunopathological mechanisms","volume":"64","author":"Tsuneyama","year":"2017","journal-title":"J Med Invest"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0155","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2020.102534_bb0160","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"Harms","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.autrev.2020.102534_bb0165","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.autrev.2020.102534_bb0170","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/flgastro-2018-101109","article-title":"Guideline review: British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines","volume":"10","author":"Goet","year":"2019","journal-title":"Frontline Gastroenterology"},{"issue":"2","key":"10.1016\/j.autrev.2020.102534_bb0175","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/BF02918614","article-title":"Complement profile in primary biliary cirrhosis","volume":"11","author":"Schlesinger","year":"1992","journal-title":"Immunol Res"},{"issue":"3","key":"10.1016\/j.autrev.2020.102534_bb0180","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1006\/clin.1998.4542","article-title":"Complement system is not activated in primary biliary cirrhosis","volume":"87","author":"Gardinali","year":"1998","journal-title":"Clin Immunol Immunopathol"},{"issue":"3\u20134","key":"10.1016\/j.autrev.2020.102534_bb0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.09.010","article-title":"Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis","volume":"33","author":"Barak","year":"2009","journal-title":"J Autoimmun"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0676.1993.tb00650.x","article-title":"Deposition of C3, the terminal complement complex and vitronectin in primary biliary cirrhosis and primary sclerosing cholangitis","volume":"13","author":"Garred","year":"1993","journal-title":"Liver"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0195","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.autrev.2020.102534_bb0200","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2007.12.023","article-title":"High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective","volume":"48","author":"Cullen","year":"2008","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0205","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1053\/gast.2001.27965","article-title":"A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis","volume":"121","author":"Mitchell","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.autrev.2020.102534_bb0210","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.autrev.2020.102534_bb0215","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/17474124.2017.1293524","article-title":"Emerging treatments for primary sclerosing cholangitis","volume":"11","author":"Rodriguez","year":"2017","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0220","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/0016-5085(89)90386-7","article-title":"Activation of the complement system in primary sclerosing cholangitis","volume":"97","author":"Senaldi","year":"1989","journal-title":"Gastroenterology"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2020.102534_bb0225","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"issue":"9","key":"10.1016\/j.autrev.2020.102534_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","article-title":"Clinical promise of next-generation complement therapeutics","volume":"18","author":"Mastellos","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2020.102534_bb0235","first-page":"1","article-title":"Current and emerging treatments for immune thrombocytopenia","author":"Dou","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.autrev.2020.102534_bb0240","article-title":"Intravenous immunoglobulin for Guillain-Barre syndrome","volume":"9","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0245","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.autrev.2020.102534_bb0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol"},{"issue":"10","key":"10.1016\/j.autrev.2020.102534_bb0255","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 comprehensive update of the Banff working group on liver allograft pathology: introduction of antibody-mediated Rejectio","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.autrev.2020.102534_bb0260","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2011.01.039","article-title":"Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation","volume":"55","author":"de Rooij","year":"2011","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.autrev.2020.102534_bb0265","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1002\/hep.23782","article-title":"Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation","volume":"52","author":"de Rooij","year":"2010","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.autrev.2020.102534_bb0270","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.23228","article-title":"Activation of the complement system in human nonalcoholic fatty liver disease","volume":"50","author":"Rensen","year":"2009","journal-title":"Hepatology"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220300896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:17:21Z","timestamp":1761599841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220300896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1568997220300896"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102534","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of complement activation in autoimmune liver disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102534"}}